Related Experiment Video
Updated: Aug 4, 2025
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
Case Report of AdAPT-001-Mediated Sensitization to a Previously Failed Checkpoint Inhibitor in a Metastatic Chordoma
Santosh Kesari1, Jeannie Williams2, Erica Burbano2
1Pacific Neuroscience Institute and Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA.
Abstract:
Chordoma is a rare, but aggressive bone tumor with a high recurrence rate that primarily arises at the cranial and caudal ends of the axial skeleton. Systemic chemotherapies are not effective against the tumor, and outside of surgical resection and radiation, no approved options are available. Prognosis depends on the extent of surgical resection, with the more the better, and adjuvant radiotherapy. Herein is presented the first-ever case of a recurrent chordoma patient that responded to the combination of one dose of an experimental TGF-beta trap carrying oncolytic adenovirus, known as AdAPT-001, followed by immune checkpoint inhibitor therapy, despite prior progression on an anti-PD-1. This case report highlights the potential of AdAPT-001 as a treatment modality in combination with checkpoint inhibition for recurrent chordoma.
Insights
A novel oncolytic adenovirus therapy (AdAPT-001) combined with immune checkpoint inhibitors shows promise for recurrent chordoma, a rare bone cancer. This combination offers a potential new treatment option for patients with aggressive, unresectable tumors.
Area of Science:
- Oncology
- Virology
- Immunotherapy
Background:
- Chordoma is a rare, aggressive bone tumor of the axial skeleton with limited treatment options.
- Current treatments include surgical resection and radiotherapy, but recurrence rates remain high.
- Systemic chemotherapy is largely ineffective for chordoma.
Observation:
- A patient with recurrent chordoma, previously progressing on anti-PD-1 therapy, received a single dose of AdAPT-001, an oncolytic adenovirus engineered with a TGF-beta trap.
- The patient subsequently received immune checkpoint inhibitor therapy.
Findings:
- The patient demonstrated a positive response to the combination therapy.
- This represents the first reported case of AdAPT-001 in combination with checkpoint inhibition for recurrent chordoma.
Implications:
- AdAPT-001 in combination with immune checkpoint inhibitors may offer a new therapeutic strategy for recurrent chordoma.
- This approach could be beneficial for patients with aggressive disease refractory to other treatments.
- Further investigation into this combination therapy is warranted for chordoma treatment.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023